Editor: What To Know
- The HYLA research clinical study is a first in human study designed to compare parameters measured by the non-invasive HYLA sensor to a standard blood gas analyzer that requires blood draw from the patient.
- Or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel .
- The HYLA sensor measurements are designed to alert physicians of sudden changes in a patient’s blood key parameters, as well as alert perfusionists of sudden changes in oxygenator performance and blood recirculation.
Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel .
The HYLA Blood sensor is a non-invasive optical blood sensor, being developed using machine learning based algorithms to measure blood key parameters, continuously and in real-time during extracorporeal procedures including VV-ECMO, VA-ECMO and open-heart surgery.
The HYLA sensor measurements are designed to alert physicians of sudden changes in a patient’s blood key parameters, as well as alert perfusionists of sudden changes in oxygenator performance and blood recirculation.
The HYLA research clinical study is a first in human study designed to compare parameters measured by the non-invasive HYLA sensor to a standard blood gas analyzer that requires blood draw from the patient. The prospective data collection will further support the final product design.
